University of Vermont

The University of Vermont Cancer Center

trials_sarcomas

Sarcomas Clinical Trials

The University of Vermont Cancer Center has many trials focused on sarcoma research.

Status: Active - Recruiting
Study Title: Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

Purpose: Chemotherapy treatment with docetaxel and gemcitabine is a standard treatment for patients with soft tissue sarcoma. This study is designed to explore whether the addition of tyrosine kinase inhibitor pazopanib enhances the anticancer effect of the chemotherapy drugs.
The Phase I component of this study is designed to determine the maximum tolerated dose of pazopanib when given with docetaxel and gemcitabine. The Phase II component is designed to determine the overall response rate of the combination of docetaxel, gemcitabine and pazopanib in patients with soft tissue sarcoma.

ClinicalTrials.gov Identifier: NCT01719302
Primary/Site/Co Investigator: Claire Verschraegen, MD
Contact: Elizabeth Eldridge (802) 656-2178
Information: http://clinicaltrials.gov/ct2/show/NCT01719302?term=Verschraegen&rank=1
Institution Number: M12-185, VCC 1202
Protocol Research Type: Investigator Initiated
Status: Active - Recruiting
Study Title:
A Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma
Purpose: The purpose of this study is to observe the effects, good and/or bad, of MLN8237  in the treatment of sarcoma.  The primary objective of the study is to determine the response rates of various sarcoma tumor types to the study drug.  Secondary objectives are to look at survival and side effects experienced by subjects with each tumor type.
ClinicalTrials.gov Identifier: NCT01653028
Primary/Site/Co Investigator: Claire Verschraegen, MD
Contact: Elizabeth Eldridge (802) 656-2178
Information: http://clinicaltrials.gov/ct2/show/NCT01653028?term=A091102&rank=1
Institution Number: M13-182, Alliance A091102
Protocol Research Type: Cooperative Group
Status: Active - Closed to Accrual
Study Title: A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
Purpose: Researchers want to find out if an Investigational drug called TH-302 can help patients with advanced soft tissue sarcoma when it is combined with doxorubicin.  The purpose of this study is to gather information on the safety and effect on your cancer of TH-302 in combination with doxorubicin.  The study will also look at how the drug is processed in the body.
ClinicalTrials.gov Identifier: NCT01440088
Primary/Site/Co Investigator:
Contact: Karen Lepuschenko (802) 656-9924
Information:
Institution Number: M12-225
Protocol Research Type: Industry

Last modified December 05 2014 11:50 AM